The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F25%3A10500653" target="_blank" >RIV/00669806:_____/25:10500653 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/25:10500653

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FkV67Dij5R" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FkV67Dij5R</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/rpor.107745" target="_blank" >10.5603/rpor.107745</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer

Popis výsledku v původním jazyce

In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an &quot;umbrella term&quot; for a variety of clinical situations.This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC). Currently, a wide range of techniques and fractionation regimens are used to treat OM-NSCLC and, unfortunately, it is not yet possible to determine which approach is the most effective. Therefore, more than ever, we should use the concept of risk-adapted RT and consider many factors when choosing the fractionation regimen and total dose applied. For different clinical scenarios, we set different treatment goals and derive different RT techniques and fractionations.Oligoprogression (OP) is a specific type of OMD that is increasingly encountered in clinical situations, probably due to the increased use of targeted therapy and the subsequent acquired resistance of a certain subpopulation of tumour cells. OP is the progression of a limited number of metastases after an initial response to systemic therapy. The rationale for using RT in areas of progression is to overcome tumour resistance in these progressive lesions.A number of trials are currently underway to find the optimal RT techniques for the most appropriate patients at a precise clinical stage.

Název v anglickém jazyce

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer

Popis výsledku anglicky

In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an &quot;umbrella term&quot; for a variety of clinical situations.This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC). Currently, a wide range of techniques and fractionation regimens are used to treat OM-NSCLC and, unfortunately, it is not yet possible to determine which approach is the most effective. Therefore, more than ever, we should use the concept of risk-adapted RT and consider many factors when choosing the fractionation regimen and total dose applied. For different clinical scenarios, we set different treatment goals and derive different RT techniques and fractionations.Oligoprogression (OP) is a specific type of OMD that is increasingly encountered in clinical situations, probably due to the increased use of targeted therapy and the subsequent acquired resistance of a certain subpopulation of tumour cells. OP is the progression of a limited number of metastases after an initial response to systemic therapy. The rationale for using RT in areas of progression is to overcome tumour resistance in these progressive lesions.A number of trials are currently underway to find the optimal RT techniques for the most appropriate patients at a precise clinical stage.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reports of Practical Oncology and Radiotherapy

ISSN

1507-1367

e-ISSN

2083-4640

Svazek periodika

30

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

11

Strana od-do

385-395

Kód UT WoS článku

001563418900001

EID výsledku v databázi Scopus

2-s2.0-105022199841